REUTERS
December 15, 2022 at 17:15 JST
Leaves of a Carmagnola hemp strain plant are silhouetted as the sun sets at a medical cannabis plantation in Trikala, Greece, August 29, 2019. (REUTERS)
The Japanese unit of Britain’s Jazz Pharmaceuticals PLC said on Thursday it had started a phase III trial of a cannabis-based drug for epilepsy.
The trial follows a recommendation by a health ministry panel in September to revise Japan’s drug laws to allow for the importation and use of medical marijuana products.
Jazz’s GW Pharma said it had administered the first dose to a patient in a late-stage trial expected to involve 84 participants, testing the efficacy and safety of the drug, Epidiolex.
Epidiolex has been approved for use in Britain and the United States and is used to treat seizures associated with severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome.
A peek through the music industry’s curtain at the producers who harnessed social media to help their idols go global.
A series based on diplomatic documents declassified by Japan’s Foreign Ministry
Here is a collection of first-hand accounts by “hibakusha” atomic bomb survivors.
Cooking experts, chefs and others involved in the field of food introduce their special recipes intertwined with their paths in life.
A series about Japanese-Americans and their memories of World War II
